Association of Cirrhosis and Cardiomyopathy.

INTRODUCTION: We investigated association of pro-BNP, troponin-I, electrocardiography (ECG) and echocardiography (ECHO) during diagnosis and identification of cirrhotic cardiomyopathy in cirrhotic patients. MATERIALS AND METHODS: Patients were divided into three groups as; compensated cirrhotic patients (group 1, n= 30), decompensated cirrhotic (group 2, n = 30) and control group (group 3, n = 30). ECHO, and ECG were performed, and troponin-I and levels of pro-BNP were analyzed. RESULTS: Average age of group 1 was 46.36 ± 16 years (range 19-86), 60% were female; group 2 was 57.03 ± 13.54 years (range 22-89), 56% female; and group 3 was 49.13 ± 0.95 years (range 18-80), 56% female. A significant increase in QTc was detected in compensated cirrhotic patients compared to the control group (p <0.05). Pro-BNP levels were significantly higher (p <0.05) in the compensated cirrhotic group compared to the control group. The levels of pro-BNP were also significantly higher in the decompensated cirrhotic group compared compensated cirrhosis group and control group (p <0.001). CONCLUSION: The increase of pro-BNP levels with severity of the disease in cirrhotic patients and the prolongation of QTc interval supports an association between these factors with cardiomyopathy. HOW TO CITE THIS ARTICLE: Sezgin B, Cindoglu C, et al. Association of Cirrhosis and Cardiomyopathy. Euroasian J Hepatogastroenterol 2019;9(1):23-26.

Is There any Association Between Celiac Disease and Helicobacter pylori?

OBJECTIVE: It was aimed to determine if there was a correlation between celiac disease (CD) and Helicobacter pylori (H. pylori) by comparing the prevalence of H. pylori in patients with and without CD. MATERIALS AND METHODS: The patients who were diagnosed with CD and tested for H. pylori and the patients who presented for gastroscopy and tested for H. pylori were evaluated retrospectively and the prevalence of H. pylori was compared. RESULTS: Fifteen (48%) of 31 patients who were diagnosed with CD and tested for H. pylori were males and had a mean age of 33.1 ± 12.7 years (17-72). In the CD group, H. pylori was positive in 15 patients (48%), and 592 antrum biopsy that was performed were included as the control group. Of these patients, 299 (50.5%) were males and had a mean age of 44.4 ± 17.05 years (16-96). Helicobacter pylori were positive in 316 patients (53.4%). Helicobacter pylori prevalence was similar in the groups with and without CD (p > 0.5). CONCLUSION: Although the prevalence of H. pylori was lower in celiac patients compared to the control group, the difference was not statistically significant. Although no findings suggesting a correlation between CD and H. pylori was found, further studies should be conducted. HOW TO CITE THIS ARTICLE: Uyanikoglu A, Dursun H, Yenice N. Is There any Association Between Celiac Disease and Helicobacter pylori? Euroasian J Hepato-Gastroenterol 2016;6(2):103-105.

Hepatic apoptotic markers are not predictors for the virological response to interferon-based therapy in chronic hepatitis C patients.

INTRODUCTION: Chronic hepatitis C virus (HCV) infection is a major health problem worldwide. The majority of cases involving HCV infection develop into chronic hepatitis because of a failure to develop an effective immune response. Apoptosis of the hepatocytes plays a significant role in the pathogenesis of HCV infection: the interaction between the Fas antigen on hepatocytes and the Fas ligand on T cells corresponds to the main mechanism for hepatocyte damage. Interferon (IFN)-α has antiviral, immunoregulatory, and antiproliferative properties, and apoptosis seems to be a critical event in the action mechanisms of both IFNs. In this study, we aimed to detect any relationship between apoptotic markers in the liver and the response to the treatment. MATERIALS AND METHODS: The study included 180 chronic HCV patients treated with IFN and ribavirin in four centers. Apoptotic markers (Fas, Fas ligand, Fas-associated death domain, caspases 3, 8, and 9, and in-situ apoptosis) were studied in the liver. The age, sex of the patients, response to therapy, ALT level, viral load, and genotype were recorded. RESULTS: The results of the study showed that the histological activity index and fibrosis correlated with CD95 staining density, caspase-8 intensiveness, and portal and parenchymal Fas ligand scores. The apoptotic parameters of the responsive cases were not significantly different from those of the unresponsive cases. CONCLUSION: The apoptotic parameters studied in liver tissue are associated with inflammation and fibrosis; however, these parameters may not predict response to treatment.

Leptin levels and lipoprotein profiles in patients with cholelithiasis.

OBJECTIVE: To determine the relationships between serum leptin and levels of lipoprotein(a) [Lp(a)], apolipoprotein A-1 (ApoA-1) and apolipoprotein B (ApoB) in patients with cholelithiasis. METHODS: Patients with ultrasound-confirmed cholelithiasis and controls frequency-matched for age, sex, body mass index, fasting blood glucose and haemoglobin A1c levels were recruited. Fasting blood samples from all study participants were assayed for glucose, haemoglobin A1c, total cholesterol, high density lipoprotein-cholesterol (HDL-C) and triglyceride. Serum Lp(a), ApoA-1 and ApoB levels were measured using nephelometric assays; serum leptin was measured using an enzyme-linked immunosorbent assay. RESULTS: A total of 90 patients with cholelithiasis and 50 controls were included in the study. Serum levels of leptin, Lp(a), total cholesterol, triglyceride and ApoB were significantly increased, and levels of ApoA-1 and HDL-C were significantly decreased, in patients with cholelithiasis compared with controls. Serum leptin in patients with cholelithiasis were significantly positively correlated with Lp(a) and ApoB and negatively correlated with ApoA-1. CONCLUSIONS: Patients with cholelithiasis have higher leptin levels and an altered lipoprotein profile compared with controls, with increased leptin levels being associated with increased Lp(a) and ApoB levels, and decreased ApoA-1 levels, in those with cholelithiasis.

Safety of peginterferon alfa-2a (40KD) treatment in patients with chronic hepatitis B infection: an observational, multicenter, open label, non-interventional study in Turkish patients.

BACKGROUND/AIMS: Pegylated alfa interferon is the only immunomodulatory drug licensed for hepatitis B. We evaluated the safety and tolerability of peginterferon alfa-2a (40KD) in patients with chronic hepatitis B. MATERIALS AND METHODS: A total of 113 chronic hepatitis B patients under peginterferon alfa-2a (40KD; 180 µg/week) treatment were included in this multicenter, open label, non-interventional study, and 66 patients completed the follow-up period. Vital signs, physical examination and laboratory findings, concomitant medications, and adverse events were recorded. A Quality of Life questionnaire (Short Form-36) was performed twice, at the beginning and at the end of the study. RESULTS: There was no significant difference between initial and last visits in terms of physical examination findings and Short Form-36 scores. A total of 27 adverse events were reported in 15 patients (22.7%), with most of them being mild in intensity (70.4%). The rates of the adverse events were similar in the monotherapy and combination therapy groups (peginterferon alfa-2a + lamivudine, peginterferon alfa-2a + adefovir or peginterferon alfa-2a + entecavir therapy groups), at 23.7% and 14.3%, respectively. The dosage of peginterferon had to be reduced in 3 patients (4.5%) due to thrombocytopenia. Overall patient compliance to treatment was detected as 85.9%. CONCLUSIONS: Based on the lack of serious adverse events and absence of impairment in Quality of Life, peginterferon alfa-2a (40KD, 180 µg/week, subcutaneously) treatment for 48 weeks led to a high level of patient compliance and was associated with a high degree of safety and tolerability for the treatment of adult patients with chronic hepatitis B in real-life practice.

Serum Lipid, Lipoprotein and Oxidatively Modified Low Density Lipoprotein Levels in Active or Inactive Patients with Behçet's Disease.

AIM: To determine serum lipid, lipoproteins and oxidized low density lipoprotein (oxLDL) levels in Behçet's disease (BD) and to evaluate the relationship of these parameters with the clinical activity of the disease. MATERIALS AND METHODS: Sixty-two patients (25 active, 37 inactive) and -26 healthy controls were included in the study. We measured serum oxLDL levels using the enzyme-linked immunosorbent assay method, and serum total cholesterol (TC), triglyceride (TG) and high density lipoprotein-cholesterol (HDL-C) levels by spectrophotometric method. RESULTS: Serum TG (108±70 mg/dL and 79±40 mg/dL, respectively; P<0.05), LDL-C (124±35 mg/dL and 108±26 mg/dL, respectively; P<0.05) and oxLDL (65±19 U/L and 53±10 U/L, respectively; P<0.01) levels were significantly higher in patients than in controls, but HDL-C levels were significantly lower in patients than in controls (39±11 mg/dL and 50±13 mg/dL, respectively; P<0.05). The levels of oxLDL in patients were found to correlate with those of TC and LDL-C. Neither the lipid parameters nor the oxLDL levels in the patients with active disease (n=25) were different than those in the patients who were in inactive stage (n=37). Serum levels of oxLDL in the patients with active and inactive disease were significantly higher than those in controls (66±19 U/L, 65±19 U/L, and 53±10 U/L, respectively; P<0.05). CONCLUSIONS: We conclude that the increase of TG, LDL-C and oxLDL levels and the decrease of HDL-levels may indicate that there is a tendency to atherothrombotic process in patients with BD. Inflammation and immunologic reactions in BD may be caused by a response to elevated oxLDL. TG, LDL-C and oxLDL are not useful markers for the severity of the disease activity.

Prevalence of microscopic colitis in patients with diarrhea of unknown etiology in Turkey.

AIM: To investigate the prevalence and demography of microscopic colitis in patients with diarrhea of unknown etiology and normal colonoscopy in Turkey. METHODS: Between March, 1998 to July, 2005, 129 patients with chronic non-bloody diarrhea of unexplained etiology who had undergone full colonoscopy with no obvious abnormalities were included in the study. Two biopsies were obtained from all colonic segments and terminal ileum for diagnosis of microscopic colitis. On histopathologic examination, criteria for lymphocytic colitis (intraepithelial lymphocyte >or= 20 per 100 intercryptal epithelial cells, change in surface epithelium, mononuclear infiltration of the lamina propria) and collagenous colitis (subepithelial collagen band thickness >or= 10 microm) were explored. RESULTS: Lymphocytic colitis was diagnosed in 12 (9%) patients (Female/Male: 7/5, mean age: 45 year, range: 27-63) and collagenous colitis was diagnosed in only 3 (2.5%) patients (all female, mean age: 60 years, range: 54-65). CONCLUSION: Biopsy of Turkish patients with the diagnosis of chronic non-bloody diarrhea of unexplained etiology and normal colonoscopic findings will reveal microscopic colitis in approximately 10% of the patients. Lymphocytic colitis is 4 times more frequent than collagenous colitis in these patients.

Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study.

INTRODUCTION: The aim of this study was to assess the efficacy and safety of esomeprazole 40 mg once daily (q.d.) in healing reflux oesophagitis at 4 and 8 weeks, and the efficacy of esomeprazole 20 mg q.d. for 12 weeks in the maintenance of remission. METHODS: A total of 235 patients with endoscopically proven reflux oesophagitis were enrolled in this study, which consisted of two phases (healing and maintenance therapy). Patients who showed complete endoscopic and symptomatic healing at the end of 4 or 8 weeks were switched to maintenance treatment with esomeprazole 20 mg q.d. for 12 weeks. The primary efficacy endpoint was healing of reflux oesophagitis at week 8. Secondary assessments included the proportion of patients with symptomatic relapse in the maintenance phase. RESULTS: At the end of week 8, 88% (95% life-table confidence intervals [CI]: 84%, 92%) of patients were healed endoscopically and 90.6% of the patients were asymptomatic. Patient age, gender and Helicobacter pylori status had no effect on the efficacy of treatment. During the 12-week maintenance treatment phase, symptomatic relapse ratios were 0.5%, 2.2%, and 0%, for the first, second, and third 4-week periods, respectively. The proportions of patients satisfied with treatment were 95% and 99.4% at the end of acute and maintenance treatment, respectively. The most common adverse effects were headache, upper respiratory tract infection and abdominal pain. CONCLUSIONS: Esomeprazole is effective in the healing of reflux oesophagitis, the resolution of heartburn, and in maintaining symptomatic remission. The effectiveness of esomeprazole in patients with gastroesophageal reflux disease is not affected by the presence of H. pylori.

Homocysteine: an activity marker in Behçet's disease?

BACKGROUND: Behçet's disease (BD) is a chronic multisystem inflammatory disorder commonly complicated by vascular thrombosis. OBJECTIVE: In this study, we investigated whether hyperhomocysteinaemia, being a well known risk factor for atherothrombogenesis, is also a contributive risk factor for the pathogenesis and the activation of Behçet's disease. METHODS: Sixty-four patients fulfilling the criteria of the International Study Group for Behçet's disease (48 males, 16 females, 33+/-8 years) were enrolled. They were separated into two groups with respect to activation features of Behçet's disease. Additionally, we collected the blood samples from 13 patients with BD in both active stage and in inactive stage. Twenty-six healthy individuals were included as a negative control group. Serum total homocysteine (Hcy) levels were determined by chemiluminescence immunoassay. RESULTS: Mean serum homocysteine concentrations in total BD patients were significantly higher than in the healthy controls (11.7+/-4.6 versus 8.7+/-2.8micromol/L, p<0.01). Mean serum homocysteine concentrations in the active patients were significantly higher than in the inactive patients and the healthy controls (13.3+/-3.6; 10.8+/-5.0; 8.7+/-2.8micromol/L, respectively) (p<0.05 and p<0.001, respectively). There was no significant difference between the patients with inactive disease and the healthy controls. When the active and the inactive stage of 13 patients with BD were compared, we found that mean serum total homocysteine levels were higher in the active stage than in the inactive stage (p<0.05). CONCLUSION: Hyperhomocysteinaemia may be responsible for the endothelial damage in BD and assumed to be a risk factor and a marker for activation of BD.

The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.

BACKGROUND/AIMS: We aimed to compare viral responses to pegylated interferon 2a plus ribavirin with pegylated interferon alpha 2b plus ribavirin. METHODS: Patients with the following characteristics were included: anti HCV(+); normal and/or elevated serum transaminase levels; positive HCV RNA by quantitative PCR; and at least stage 1 fibrosis according to Knodell Scoring System on liver biopsy. Patients were assigned into two groups. Group 1 consisted of 37 patients (24 female, 13 male) who received pegylated interferon alpha 2a 180 microg s.c. weekly plus ribavirin adjusted for patient's weight. All patients were genotype 1. Group 2 consisted of 37 patients (27 female, 10 male) who received pegylated interferon alpha 2b 1.5 microg/kg s.c. weekly plus ribavirin adjusted for patient's weight. At week 24, the treatment was discontinued in patients positive for HCV RNA by PCR, while patients negative for HCV RNA continued treatment up to 48 weeks. The end of treatment and sustained virologic responses of the patients were ascertained by assessing HCV RNA levels at the end of the treatment and after 24 weeks follow-up after the cessation of treatment. RESULTS: At week 48, the proportion of patients with negative HCV RNA (end of treatment viral response) was 28/37 (75.7%) in Group 1 and 27/37 (73%) in Group 2. The group sustained virologic response rates were 48.6% and 35.1% for Group 1 and Group 2, respectively. No significant differences were noted between the two groups. CONCLUSION: The two pegylated interferon molecules were similar in terms of sustained virologic response rate.

Assessment of bone metabolism and mineral density in chronic viral hepatitis.

BACKGROUND/AIMS: The aim of the study was to assess bone metabolism and impact of disease on bone mineral density in patients with non-cirrhotic chronic hepatitis B or C. METHODS: 105 patients with chronic hepatitis B or C receiving antiviral agents and 60 healthy controls were included. Subgroups (n=15) were defined on the basis of age (males) or menopausal status (females). Bone mineral density; serum parathyroid hormone (PTH), calcium (Ca), phosphorus (P), total alkaline phosphatase, and 25-hydroxy vitamin D levels; 24-hour urinary levels of Ca and P; and urinary telopeptide (NTX) were measured. Statistical comparisons were made between patient groups and the matched controls. RESULTS: Compared to controls, the average serum levels of PTH were lower and 24-hour urinary mean Ca levels and T scores were higher in chronic hepatitis B patients between 20 and 40 years of age. Men with chronic hepatitis B and aged 40 - 65 years had lower mean serum P concentrations. Postmenopausal women with chronic hepatitis B had significantly higher NTX levels. Men with chronic hepatitis C had significantly elevated levels of 24-hour mean urinary P levels. The serum 25 OH vitamin D levels were significantly higher in premenopausal women with chronic hepatitis C. Postmenopausal women with chronic hepatitis C had significantly lower serum P concentrations. Other parameters and T scores did not differ significantly between patient groups and matched controls. CONCLUSION: Our results suggest that chronic hepatitis B and C infections do not pose a risk for osteoporosis and low bone mineral density.

Predictive value of morphologic characteristics in rectosigmoid adenomatous polyps for the probability of synchronous polyps or cancer in the proximal colon.

BACKGROUND/AIMS: Sigmoidoscopy is performed more frequently than colonoscopy, especially for screening purposes and searching for colorectal neoplasm. The necessity of colonoscopy in patients with an adenoma ofor=11 mm) polyps. These groups were compared regarding the presence of proximal adenoma and advanced proximal neoplasia (>10 mm adenoma and/or villous histology and/or high grade dysplasia or cancer). Polyps found in the rectum and sigmoid colon were considered as distal polyps and polyps other than these were considered as proximal polyps. RESULTS: In this study, of 1124 consecutive patients who underwent colonoscopy between April 1997 and January 2002, 184 (16%) had 258 adenomatous polyps in the rectosigmoid area. The polyps were diminutive (or=11 mm) in 33 patients. Forty-one of the patients (39%) with diminutive polyps, 20 of the patients (43%) with small polyps and 19 of the patients (57%) with large polyps had neoplasm in the proximal bowel. In these patients, advanced proximal neoplasm was found in 8 (8%), in 6 (13%) and in 11 (33%), respectively. There was no difference regarding the presence of neoplasm in the proximal colon between these groups. The rate of advanced proximal neoplasm was found to be significantly higher in the group with large polyps in the rectosigmoid area than in the groups with small and diminutive polyps (p<0.05). In 104 patients (57%) with polyp(s) in rectum and sigmoid colon, no associated polyp or cancer was encountered in the proximal colon. CONCLUSION: Colonoscopy is indicated when adenomatous polyp, regardless of size, is found on rectosigmoidoscopy performed because of symptoms.

HCV prevalence in Hodgkin and non-Hodgkin lymphoma cases.

BACKGROUND/AIMS: In this study we aimed to investigate the relation between hepatitis C virus (HCV) and B cell lymphoproliferative diseases. METHODS: Eighty-four patients with B-cell non-Hodgkin lymphoma and 50 patients with Hodgkin lymphoma were included. Control group consisted of another 100 otherwise healthy blood donors who had no previous history of invasive surgery, blood transfusions, and viral hepatitis. HCV positivity was investigated in both case groups and control group. RESULTS: Anti-HCV positivity was significantly more frequent in B-cell non-Hodgkin lymphoma patients compared to control group (7.1% vs. 1%, p<0.05). In Hodgkin lymphoma patients however, frequency was comparable with the control group (2% vs. 1%, p<0.05). CONCLUSIONS: These findings suggest that HCV may play a role in the development of B-cell non-Hodgkin lymphoma, but not in Hodgkin lymphoma.

Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial.

We aimed to compare the efficacy of interferon-alpha2b (IFN) induction treatment in combination with ribavirin to IFN induction alone in chronic hepatitis C. In total, 125 patients (66 male, 59 female, mean age: 48 +/- 9, range: 21-70) were enrolled and randomized into two arms: In the first, patients received 5 MU/day of IFN for 4 weeks followed by 3 MU/day for the next 4 weeks. Treatment was continued with 3 MU three times a week IFN for an additional 40 weeks. Ribavirin was administered 1000-1200 mg/day according to the body weight for the entire 48-week period. In the second arm, patients received placebo in addition to IFN. Fifty-nine patients were placed in the ribavirin arm and 66 in placebo arm. All patients were genotype 1. At week 48, 24/66 (36%) from the placebo and 31/59 (52%) from the ribavirin group responded (P > 0.05). However, during the 24-week untreated follow-up period, 13/24 (54%) from the placebo, and 8/31 (26%) from the ribavirin group relapsed (P = 0.002.), resulting in a sustained virologic response (SVR) rate of 17% in the placebo and 39% in the ribavirin group (P = 0.005.) In conclusion, IFN induction treatment in combination with ribavirin is superior to IFN induction treatment alone in genotype 1 patients, and the SVR rate of 39% is encouraging.